Prelude Therapeutics Q4 2022 Earnings Report $1.18 -0.01 (-0.84%) As of 12:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Prelude Therapeutics EPS ResultsActual EPS-$0.60Consensus EPS -$0.63Beat/MissBeat by +$0.03One Year Ago EPSN/APrelude Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APrelude Therapeutics Announcement DetailsQuarterQ4 2022Date3/15/2023TimeN/AConference Call ResourcesPress ReleasePRLD Earnings HistoryPowered by Prelude Therapeutics Earnings HeadlinesKrishna Vaddi Bought 4.9% More Shares In Prelude TherapeuticsDecember 22, 2024 | uk.finance.yahoo.comFueling growth: The Innovation Space powers breakthroughs in life sciences, clean technologies, and advanced materialsDecember 20, 2024 | bizjournals.comThese guys expect TSLA to reach $700 a share by AugustTwitter lit up this morning after someone put a $4,000,000 bet on TSLA. These guys lit up the $700 strike calls for August 2025… This is odd, considering Tesla only trades for around $350 a share today… In other words, these guys are betting that Tesla’s stock will surge by 100% over the months ahead. In my opinion, that’s an incredibly risky bet. A lot can happen between now and then… Besides, there is a better way to target that same 100% return without waiting until August.January 31, 2025 | WealthPress (Ad)Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527December 13, 2024 | msn.comPrelude Therapeutics (PRLD) Gets a Sell from Morgan StanleyDecember 12, 2024 | markets.businessinsider.comPrelude Therapeutics presents first interim data from trial of PRT2527December 12, 2024 | markets.businessinsider.comSee More Prelude Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Prelude Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prelude Therapeutics and other key companies, straight to your email. Email Address About Prelude TherapeuticsPrelude Therapeutics (NASDAQ:PRLD), a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.View Prelude Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings NXP Semiconductors (2/3/2025)Palantir Technologies (2/3/2025)PayPal (2/3/2025)Mitsubishi UFJ Financial Group (2/3/2025)Amgen (2/4/2025)Advanced Micro Devices (2/4/2025)Alphabet (2/4/2025)Alphabet (2/4/2025)Mondelez International (2/4/2025)Apollo Global Management (2/4/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
